SCHEMBL4930591

SCHEMBL4930591

FC(F)(F)COc1ccc(-n2c(SCc3ccc(Cl)cc3)nc3cc(Cl)ccc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.44
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
FADS1 O60427 1/20 0.41
TP53 P04637 1/20 0.40
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4922716 0.99 DRD2 (0.43) DRD2HTTNPSR1LMNASMN1; SMN2
SCHEMBL4921631 0.92 DRD2 (0.46) DRD2HTTNPSR1LMNASMN1; SMN2
Hydrochloric Acid SCHEMBL4921709 0.91 DRD2 (0.45) DRD2HTTNPSR1LMNASMN1; SMN2
SCHEMBL4925813 0.91 DRD2 (0.43) DRD2HTTNPSR1LMNASMN1; SMN2
SCHEMBL4928384 0.88 DRD2 (0.43) DRD2LMNASMN1; SMN2TP53
Hydrochloric Acid SCHEMBL4931151 0.87 DRD2 (0.42) DRD2LMNASMN1; SMN2TP53
SCHEMBL4930398 0.86 HTT (0.53) HTTNPSR1LMNASMN1; SMN2L3MBTL1
Hydrochloric Acid SCHEMBL4921899 0.85 HTT (0.52) HTTNPSR1LMNASMN1; SMN2L3MBTL1
SCHEMBL14280750 0.84 HTT (0.45) HTTNPSR1LMNASMN1; SMN2L3MBTL1
SCHEMBL14280751 0.84 NPC1 (0.46) HTTNPSR1LMNASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US claimed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP claimed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 DRD2 2198/4885HTT 4035/4885NPSR1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.